(A (S (C 62nd Annual Scientific Meeting American Society of Cytopathology



Lung Cancer Detection with LuCED[®]: A Non-Invasive Test Based on 3D Cell-CT[®] of Cells in Sputum

Michael Meyer, CTO





Full Disclosure

Employed as CTO at VisionGate, Inc.



Lung Cancer Dilemma


- 31 million US patients at high risk for lung cancer
- 160,000 die each year largest cancer killer
- Potential methods of screening
 - Sputum cytology Meta-data analysis Chest, 2003:
 - Average sensitivity = 60.4%, Average specificity = 98.1%
 - Low-Dose CT (LDCT) NLST study NEJM, 2011:
 - 20% reduction in mortality
 - Recent CMS decision to reimburse LDCT
 - 94% false positive rate (specificity = 6%)





The LuCED[®] Test

- Morning spontaneous or induced sputum
- Cell-CT: sub-micron resolution, isometric 3D cell imaging
- Highly accurate, automated, abnormal cell recognition
- Potentially resolves LDCT false positive issue













3D vs. 2D Cell Imaging

Critical for *Machine* recognition of abnormal cells



2D: Objects are overlapped and often out of focus3D: Each cell is analyzed separately

2D: Image may not contain critical morphology3D: Cell is represented comprehensively




3D: Critically important morphology "seen"<u>only</u> in 3D



(A (S (C 62nd Annual Scientific Meeting American Society of Cytopathology

Abnormal Cell Detection

- 1. 594 features are computed on every cell:
 - e.g. N/C ratio, chromatin distribution, nuclear pleomorphism, etc.
- 2. Final normal/abnormal cell diagnosis by a cytopathologist




LuCED Workflow

(A(S(C

62nd Annual Scientific Meeting American Society of Cytopathology

Cytology for the 21st Century

Internet




Sputum Adequacy

(A(S(C

Scientific Meeting American Society of Cytopathology

Criterion for sufficient sampling of the lung






(A (S (C 62nd Annual Scientific Meeting American Society of Cytopathology

LuCED Case Sensitivity

Adequate Cases	Abnormal Cells Present	Abnormal Cells Detected	Sensitivity
47	45	44	93.6%



Consistent sensitivity across tumor histology, stage and size *Early stage (I & II) detection rate = 94.1%*

LuCED Case Specificity

- Sputum from 47 patients without NSCLC or SCLC
 - 4 clinics worldwide

Scientific Meeting American Society of Cytopathology

- 11 COPD, chondroma, lymphoma, inflammation, emphysema, 9 benign lesions, 26 normal
- 609 FP/122,005 cells or 99.5% cell specificity by the LuCED classifier before cytologist adjudication
- No significant variation by disease state

Positive Cells are Resolved by the Cytologist for Essentially 100% Case Specificity





Conclusions

LuCED case sensitivity:

- >94% for early stage lung cancer
- Independent of tumor histology, stage and size

LuCED case specificity:


• ~100% case specificity following cytologist review

LuCED addresses LDCT false positive indications and confirms positive diagnoses for cost-effective lung cancer screening





Questions



VisionGate acknowledges these collaborators who supplied specimens for this study

- Aristotle University Thessaloniki, Greece, PI: Dr. Paul Zarogoulidis
- Baptist Cancer Center Jacksonville, Florida, USA: PI: Dr. Douglas Johnson
- Fred Hutchinson Cancer Research Center Seattle, Washington, USA, PI: Dr. Jason Chien
- Sheba Medical Center TelHashomer, Israel, PI: Dr. Nir Peled
- Swedish Hospital Seattle, Washington, USA, PI: Dr. Ralph Aye
- VU University Amsterdam, Netherlands, PI: Dr. Eric Thunnissen

VisionGate also acknowledges Dr. David Wilbur for assistance with cell diagnosis